Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
34
TTNP Quote, Financials, Valuation and Earnings
Last price:
$3.54
Seasonality move
:
9.03%
Day range:
$3.25 - $3.64
52-week range:
$3.14 - $14.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.79x
Volume:
36.9K
Avg. volume:
29.7K
1-year change:
-37.9%
Market cap:
$3.2M
Revenue:
$1K
EPS (TTM):
-$6.54
Analysts' Opinion
-
Consensus RatingTitan Pharmaceuticals has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Titan Pharmaceuticals has an estimated upside of 3940.4% from its current price of $3.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $3.47.
Fair Value
-
According to the consensus of 0 analysts, Titan Pharmaceuticals has 3940.4% upside to fair value with a price target of -- per share.
TTNP vs. S&P 500
-
Over the past 5 trading days, Titan Pharmaceuticals has underperformed the S&P 500 by -2.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Titan Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Titan Pharmaceuticals revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Titan Pharmaceuticals reported revenues of --.
Earnings Growth
-
Titan Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Titan Pharmaceuticals reported earnings per share of -$2.29.
Enterprise value:
-923.3K
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Income Statement | ||||||
| Revenue | $50K | -- | -- | $1K | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$9.4M | -$8.5M | -$7.1M | -$1.6M | -$2.1M | |
| EBITDA | -$9.2M | -$8.4M | -$7.1M | -$1.5M | -$2.1M | |
| Diluted EPS | -$17.40 | -$11.33 | -$6.54 | -$2.11 | -$2.29 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.7M | $10.6M | $7.7M | $498K | $4.4M | |
| Total Assets | $9.8M | $11.5M | $8.3M | $812K | $4.4M | |
| Current Liabilities | $4.9M | $2.5M | $2.5M | $1.8M | $356K | |
| Total Liabilities | $8.2M | $2.8M | $2.7M | $1.8M | $356K | |
| Total Equity | $1.6M | $8.7M | $5.7M | -$1M | $4M | |
| Total Debt | $5M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8.1M | -$6.5M | -$6.8M | -$1.1M | -$2.1M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $5M | -- | -- | -- | -- | |
| Free Cash Flow | -$8.1M | -$6.5M | -$6.8M | -$1.1M | -$2.1M | |
TTNP
Sector
Market Cap
$3.2M
$46.1M
Price % of 52-Week High
23.41%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-37.9%
-30.52%
Beta (5-Year)
1.122
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$3.39
200-day SMA
Sell
Level
$5.69
Bollinger Bands (100)
Sell
Level
3.68 - 5.96
Chaikin Money Flow
Sell
Level
-1.2B
20-day SMA
Sell
Level
$3.60
Relative Strength Index (RSI14)
Sell
Level
44.31
ADX Line
Sell
Level
20.03
Williams %R
Neutral
Level
-62.0794
50-day SMA
Sell
Level
$3.91
MACD (12, 26)
Sell
Level
-0.18
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
1.3B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-67.1557)
Sell
CA Score
(Annual)
Level (-5.1377)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (9.0699)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Stock Forecast FAQ
In the current month, TTNP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TTNP average analyst price target in the past 3 months is --.
-
Where Will Titan Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Titan Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Titan Pharmaceuticals?
Analysts are divided on their view about Titan Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Titan Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Titan Pharmaceuticals's Price Target?
The price target for Titan Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TTNP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Titan Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of TTNP?
You can purchase shares of Titan Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Titan Pharmaceuticals shares.
-
What Is The Titan Pharmaceuticals Share Price Today?
Titan Pharmaceuticals was last trading at $3.54 per share. This represents the most recent stock quote for Titan Pharmaceuticals. Yesterday, Titan Pharmaceuticals closed at $3.47 per share.
-
How To Buy Titan Pharmaceuticals Stock Online?
In order to purchase Titan Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
